How do I buy Spero Therapeutics, Inc. Common Stock (SPRO) stock?

Buying Spero Therapeutics, Inc. Common Stock (SPRO) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "SPRO", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy SPRO by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if SPRO is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Spero Therapeutics, Inc. Common Stock (SPRO) Stock

NASDAQ · SPRO

Trade SPRO

Fundamentals

Market cap

$66.97M

Price / Earnings ratio

9.3x

Price / Sales ratio

1.5x

Price / Book ratio

1.6x

Return on assets

13.0%

Dividend amount

$0.00

Dividend yield

0.00%

Source: third-party data provider, as of October 14, 2026

Compare with SPRO

Technical indicators

RSI 14: 44.45
MACD 12/26/9: -0.02
EMA 9 of MACD: -0.02
MACD histogram: -0.00
SMA 50: $1.20; Price below SMA 50
EMA 50: $1.29; Price below EMA 50
SMA 200: $2.07; Price below SMA 200
EMA 200: $1.90; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 1 analyst rating

Strong Sell0

Sell0

Hold0

Buy1

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

No data available

Debt & Balance Sheet

No data available

Revenue to Profit

No data available

Earnings

No data available

Source: third-party data provider

About Spero Therapeutics, Inc. Common Stock

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

SectorHealthcare

IndustryBiotechnology

Employees25

CEOMs. Esther P. Rajavelu

IPO DateNov 2, 2017

HeadquartersCambridge, MA

Key Executives

Name	Title	Year Born
Ms. Esther P. Rajavelu	CEO, President, CFO, Chief Business Officer, Treasurer & Director	1979
Mr. Timothy Keutzer	Chief Operating Officer	1968
Mr. John Raymond	Senior Vice President of Finance & Business Operations	—
Dr. Debra Jeske Zack M.D., Ph.D.	Chief Medical Officer	1957
Ms. Sheila Finan	Senior VP & Controller	—

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026					+11.0	-21.9	-47.3	+6.1	+0.8	-8.7

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Spero Therapeutics, Inc. Common Stock (SPRO) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "SPRO", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy SPRO by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Spero Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Spero Therapeutics, Inc. Common Stock (SPRO) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track SPRO's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Spero Therapeutics, Inc. Common Stock (SPRO) Stock

Fundamentals

Compare with SPRO

Recent news

Spero Therapeutics Q2 Earnings Call Highlights

Spero Therapeutics Q2 Earnings Call Highlights

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Spero Therapeutics Q2 Earnings Call Highlights

Spero Therapeutics Q2 Earnings Call Highlights

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

New Strong Buy Stocks for November 15th

New Strong Buy Stocks for November 15th

Spero's stock jumps 188% after GSK licenses experimental antibiotic

Spero's stock jumps 188% after GSK licenses experimental antibiotic

About Spero Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade